•Inclusion Criterion changed, requiring male subjects to use a medically acceptable method of birth control throughout their participation in the study and to report any pregnancy of a partner. •Exclusion Criterion was rewritten to clarify that exclusion required both a hemoglobin of less than equal to (<=) 10 g/dL and a platelet count of <=80 x 103 platelets/cubic millimetre(mm3). •Anaphylactoid reaction during treatment with imiglucerase in addition to anaphylactic reaction as a reason for exclusion from the study. •Expanded exclusion of erythropoietin to exclusion of any red cell growth factor and allowed the use of inhaled corticosteroid therapy. •Provided clarification that a spleen infarction was required to be active and clinically significant, experienced within 12 months of screening, and radiologically confirmed to be a reason for exclusion from the study and splenectomized subjects were not to be excluded. •Provided clarification that bone necrosis was to be worsening bone necrosis within 12 months of screening; inactive or stable bone necrosis was not intended to be an exclusion. •Pregnant or lactating subjects were excluded. •The following assessments were added to screening procedures: chitotriosidase genotyping, vital signs, and serum B12 and folic acid concentrations. •After each of the first 3 infusions, a safety telephone call from the Investigator to the subject 1 day after infusion was added to the protocol. •Infusion time was changed from the same infusion time as the previous imiglucerase dose to a 1-hour infusion. Longer infusion times were to be documented. •Transition to home therapy no longer required approval by the Shire HGT Medical Monitor but was left to the discretion and direction of the Investigator. •Reticulocyte count was to be performed at the site’s local laboratory rather than a central laborator due to stability issues. •Imaging of the femoral neck was added to the dual-energy x-ray absorptiometry (DXA) assessment.